Pro 2014-012 (Announcement of Jianfeng Group on the Sale of Tianjin Jianfeng Equity)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2014-012
浙江尖峰集团股份有限公司
关于出售子公司股权的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l交易简要内容:本公司的控股子公司浙江尖峰药业有限公司持有天津市尖峰天然产物研究开发有限公司54.5%的股权,本次尖峰药业与法国Diana Naturals SAS公司签订了《有约束力的框架协议》,拟以6322万元(人民币)的价格出售该股权。
l本次交易不构成关联交易
l本次交易不构成重大资产重组
l交易实施不存在重大法律障碍
l本次签订的为有约束力的框架协议,还需经双方进一步谈判和协商,在达成正式股权转让协议并经相关政府部门批准后实施。
一、交易概述
(一)本公司的控股子公司浙江尖峰药业有限公司(以下简称“尖峰药业”)持有天津市尖峰天然产物研究开发有限公司(以下简称“尖峰天然产物”)54.5%的股权。2014年5月28日,尖峰药业与法国Diana Naturals SAS(以下简称“戴安娜天然”)签订了《有约束力的框架协议》-受制于先决条件和合同(以下简称“框架协议”),拟以6322万元(人民币)的价格向戴安娜天然或其指定的买方出售该股权。本次交易不构成关联交易。
(二)董事会审议情况
本公司于2014年5月28日以通信方式召开了八届十六次董事会,公司八名董事全部参加了会议,经审议与表决,董事会以8票同意、0票反对、0票弃权审议通过了该股权转让事宜。
(三)根据公司章程的规定,该股权转让事宜不需报股东大会审议。本次签订的仅为有约束力的框架性协议,后续双方将进一步谈判和协商,在达成正式股权转让协议并经相关政府部门批准后实施。
二、交易对方情况介绍
(一)基本情况
1、企业名称:Diana Naturals SAS
2、注册地:5 rue de la Gare, BP 15, 35560 Antrain, 法国
3、法定代表人:Jean-Yves Parisot
4、注册资本:9,511,920欧元
5、企业性质:简单股份制公司
6、主要办公地点:5 rue de la Gare, BP 15, 35560 Antrain,法国
7、主营业务:戴安娜天然主要从事生产和销售源自天然原料的功能性食品解决方案。
8、控制人:戴安娜天然的控制人为 Diana SAS。
(二)交易对方发展状况
戴安娜天然是戴安娜集团食品部的组成部分,戴安娜集团成立于1990年,是一家针对食品、宠物食品、保健品、水产养殖及化妆品产业提供天然感官与功能性解决方案的法国生物科学公司,主要业务划分为三大领域:食品、宠物食品和健康营养。
戴安娜天然2013年的营业收入为1.33亿欧元,2013年末的资产总额为1.67亿欧元、资产净额为2千3百万欧元,财务数据未经审计。
三、交易标的基本情况
1、交易标的:天津市尖峰天然产物研究开发有限公司的54.5%的股权;
2、注册资本:1000 万元(人民币);尖峰药业占54.5%股权;
3、设立时间:1999年12月;
4、注册地点:天津市经济开发区12大街南黄海路西;
5、主营业务:研究、生产和销售天然植物提取产品;
6、尖峰天然产物的经营和财务情况(2013年数据经具有从事证券、期货业务资格的天健会计师事务所审计,2014年一季度数据未经审计):
|
项目(万元人民币) |
2013年末 |
2014年一季度末 |
|
资产总额 |
8680.41 |
9101.96 |
|
负债总额 |
4493.24 |
4757.73 |
|
净资产 |
4187.17 |
4344.23 |
|
|
2013年 |
2014年一季度 |
|
营业收入 |
10054.52 |
2417.36 |
|
利润总额 |
866.98 |
184.77 |
|
净利润 |
763.41 |
157.06 |
7、资产权属:本次出售的股权无设定担保、抵押及其它任何转让的情况,无涉及该资产的诉讼、仲裁或司法强制以及其它重大争议事项。
四、协议的主要条款
“DIANA” 或“买方”:Diana Naturals SAS或任何其他Diana Naturals SAS或戴安娜集团指定取代其签署股权转让协议的关联公司
“尖峰药业”或“卖方”:浙江尖峰药业有限公司
2014年5月28日,双方签订了一份有约束力的框架协议,协议的主要内容如下:
(一)交易范围
买方确认其有意直接或通过任何其指定的实体收购尖峰天然产物100%的股权,其中向卖方收购其持有的54.5%的股权。
(二)交易对价和估值基础
买方为收购卖方所持有的尖峰天然产物54.5%股权提出交易对价为人民币陆仟叁佰贰拾贰万元(RMB 6322万元)的有约束力的要约, 而该要约为卖方所接受,前提是本交易项下的尖峰天然产物100%股权均出售给买方,并且此要约受制于下文所列的签署前预设条件和股权转让协议的条件。交易对价为各方基于对尖峰天然产物截至2013年12月31日(“基准日”)的财务报表以及全面尽职调查的结果,经双方谈判商定的公司整体价值而确定。
(三)卖方在股权转让协议签署前保证完成的事项
1、卖方同意使买方得以对其分别大约10个关键客户和供应商进行访谈, 以验证与上述合作伙伴的业务的真实性和可持续性;
2、100%尖峰天然产物的股东(“所有卖方”)都应签署与本框架协议的条款和条件实质相同的另一份框架协议;
3、尖峰天然产物所有个人股东签署文件授权尖峰药业董事长代表所有个人股东协商股权转让协议,但所有个人股东均应受买方和蒋先生协商并达成一致的股权转让协议的约束,并分别签署该股权转让协议;
4、在本框架协议签署后,卖方将允许买方查阅尖峰天然产物2013年的最终财务报表;
5、在签署股权转让协议之前, 在不违背中国法律,并在中国政府允许的情况下,将由一家具有资质的天津环境评估公司进行若干有关地下水和土壤污染的标准检测(费用由买方承担)。 评估公司的选择将由各方同意确认;
6、尖峰天然产物取得果蔬粉车间的房地产权证;
7、向有关政府部门取得正式的书面函同意二期土地(定义见下文)的建设延迟至2015年12月;
8、买方将审阅尖峰天然产物准备向有关部门提交的更新高新技术企业(“高新企业”)证书的申请文件;
9、尖峰天然产物总经理承诺在其所得报酬不低于目前水平的前提下,继续在尖峰天然产物任职至少24个月(自交易的交割日起计算);
10、尖峰天然产物现任副董事长在和买方就报酬达成协议的前提下签署顾问合同
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05